funding probability score
total disclosed funding
last round valuation estimate
disclosed funding rounds
latest round
latest funding stage
next round estimate
development stage
number of investors
number of competitors
monthly web visits
twitter followers
United States
HQ address
1300 York Avenue, New York, 10065, USA
Angiocrine Bioscience, Inc. has developed the VeraVec endothelial cell platform for amplifying stem and progenitor cells by recapitulating the in vivo vascular niche in vitro. The technology has clear application to angiogenesis, stem cell transplant, iPSC culture, and regenerative medicine. Recent publications have also demonstrated the utility of the VeraVec endothelial platform for the cultivation of malignant cells in addition to their healthy counterparts. Co-culture experiments are applicable to both conventional 2D monolayers and more advanced 3D applications in a variety of protein matrices. These advances take advantage of the endogenous property of endothelial cells to secrete numerous growth factors, termed angiocrine factors, which is maintained by the VeraVec platform.

Angiocrine also offers a range of cell products to support basic research. The VeraVec products consist of both human and mouse endothelial cells (with other species in the pipeline) that adapt to cell culture in a variety of media formulations, including serum-free conditions in several of our products, and yet maintain the phenotypes and behaviors expected of primary cells through many passages.


There is much more to this profile.
Log in or sign up for free to see the whole thing.

Get free access to these powerful tools:
- Advanced search filters
- Full startup and investor profiles
- Follow startups and investors
- Custom follow-lists
- Startup benchmarking
- Network maps
- Market stats